Figure 2From: Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review Overall survival. EST-3886, median follow-up 11.9 years; RTOG-85-31, median follow-up 6.5 years; Granfors 2006, follow-up 14–19 years; AST, androgen suppression therapy. (This figure should be published in the manuscript).Back to article page